Epipregnanolone

The antagonist-leaning fourth tetrahydroprogesterone isomer: a 3beta,5beta pregnane that blocks allopregnanolone at GABA-A while modulating NMDA and T-type calcium channels.

Epipregnanolone is an endogenous progesterone metabolite rather than an approved drug or marketed supplement, and it has no established human safety profile; it is not sold over the counter in the way DHEA or pregnenolone are. Essentially all pharmacological data come from in vitro preparations and from rodent studies using injected doses in the milligram-per-kilogram range that do not correspond to any human exposure.

Because it acts as an antagonist or weak partial agonist at the GABA-A neurosteroid site, it could in principle oppose the calming, anticonvulsant, and sedative actions of allopregnanolone, though this has not been evaluated clinically. Its sulfate ester engages NMDA receptors and TRPM3 channels and the parent blocks T-type calcium channels, so off-target ion-channel effects are plausible at high concentrations. There is no basis for self-administration, and endogenous fluctuations around pregnancy and the menstrual cycle are the main context in which humans are meaningfully exposed.

Epipregnanolone was known for decades as a minor, ring A-reduced saturated metabolite of progesterone catalogued in steroid-metabolism studies of muscle, myometrium, and bone marrow during the 1970s. Its neuropharmacology emerged between 1990 and 1993, when work on cortical neurons and, most influentially, the radioligand-binding studies of Prince and Simmonds identified 5beta-pregnan-3beta-ol-20-one as a specific antagonist at the neurosteroid site of the GABA-A receptor and used it to argue for multiple steroid binding sites. In 1997 the laboratory of Farb and colleagues placed its sulfate ester on the map of NMDA-receptor pharmacology as a negative modulator acting at a site distinct from pregnenolone sulfate.

Through the 2000s, Czech groups led by Hill and Parizek quantified epipregnanolone and its conjugates in maternal and umbilical blood, establishing it as a genuine endogenous circulating neurosteroid, while behavioral pharmacologists probed its effects on alcohol reinforcement and tolerance. A distinct analgesia strand followed in 2014 with the demonstration that it blocks CaV3.2 T-type calcium channels in sensory neurons. Interest has continued into the 2020s with native-neuron electrophysiology revisiting its GABA-A actions, medicinal-chemistry efforts to build positive NMDA modulators on the pregnane scaffold, and the 2025 discovery that gut bacteria can synthesize it.

Within neuroscience, epipregnanolone occupies a niche as the antagonist member of the tetrahydroprogesterone quartet and as a stereochemical control compound; because it differs from the sedative potentiators only in ring geometry and hydroxyl orientation, it is prized for probing the structure-activity rules of neurosteroid action at GABA-A, NMDA, and T-type calcium channels. It has no reputation as a consumer nootropic or supplement and is not sold for human use.

It is frequently confused with sepranolone (isopregnanolone, the 3beta,5alpha isomer), which shares the anti-allopregnanolone behavior and has itself reached clinical trials for premenstrual dysphoric disorder; epipregnanolone is the 5beta relative of that molecule and remains a laboratory and endogenous-biomarker compound. Among researchers its most durable contributions are as a pharmacological tool for dissecting neurosteroid binding sites and, more recently, as a template for T-type calcium-channel analgesics and pregnane-based NMDA modulators.